Pfizer Inc. (NYSE: PFE) has announced the release of five-year follow-up data for its kinase inhibitor Lorbrena/Lorviqua (lorlatinib) in untreated ALK-positive advanced non-small cell lung cancer (NSCLC). The data revealed that Lorbrena demonstrated an 81% reduction in the rate of disease progression or death compared to Xalkori (crizotinib), and increased the rate of patients alive without disease progression from 8% to 60%.
Furthermore, Lorbrena showed a 94% reduction in the risk of developing intracranial progression, with no new safety signals identified.
As stated in the press release, Lorbrena is approved in the United States for the treatment of metastatic ALK-positive NSCLC.- Flcube.com
